Compare iShares JPMorgan USD Emerging Markets Bond ETF (EMB) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares JPMorgan USD Emerging Markets Bond ETF vs TG Therapeutics Inc — how do they compare? iShares JPMorgan USD Emerging Markets Bond ETF trades at $91.05 (market cap $12.87B), while TG Therapeutics Inc trades at $55.16 (market cap $8.16B). The key difference: iShares JPMorgan USD Emerging Markets Bond ETF is the larger of the two by market cap, and TG Therapeutics Inc is trading nearer its 52-week high, iShares JPMorgan USD Emerging Markets Bond ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares JPMorgan USD Emerging Markets Bond ETF for 50 Days and TG Therapeutics Inc for 15 Days on average.
| EMB | TGTX | |
|---|---|---|
Market Cap | $12.87B | $8.16B |
Volume | 14,946,002 | 1,735,121 |
Sector | Fixed Income | Health |
52-Week High | $97.74 | $59.06 |
52-Week Low | $90.14 | $26.94 |
Typical Hold Time | 50 Days | 15 Days |
Enterprise Value | — | $8.37B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EMB trades at $90.96 with minimal daily movement (+0.2%), showing technical bearish signals from moving averages while oscillators remain neutral. The stock faces resistance at $91-92 with support at $90. Recent dividend declarations of $0.41-0.44 per share provide income appeal, though key financial ratios remain undisclosed in current data.
The outlook appears cautious with technical indicators signaling bearish momentum. Income-focused investors may find value in the dividend yield, but limited fundamental data availability and bearish technical signals suggest careful evaluation is warranted. Market risks include broader economic pressures affecting bond yields and emerging market exposure.
TG Therapeutics (TGTX) trades at $54.96, up 3.8% with strong fundamentals including 82.37% gross margins and 100.28% ROE, though recent earnings misses and a negative cash flow of -$100.70M in 2025 raise concerns. Technical indicators show bearish momentum with support at $51-$52, while news highlights BRIUMVI's market share gains and potential acquisition interest.
The outlook remains mixed: analyst consensus is bullish with an $80.50 price target, but risks include ongoing litigation, earnings volatility, and competitive pressures. Upside potential hinges on BRIUMVI's continued growth and pipeline advancements, making TGTX a high-risk, high-reward biotech play.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About iShares JPMorgan USD Emerging Markets Bond ETF
EMB invests in U.S. dollar-denominated sovereign debt from emerging market countries. It provides exposure to government bonds from dozens of nations like Turkey, Mexico, and Brazil, offering a way to seek higher yields and geographic diversification.
Read more on EMB →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
